To include your compound in the COVID-19 Resource Center, submit it here.

HTI-501: Interim Phase I/II data

Interim data from the open-label, dose-escalation Phase I portion of a blinded, placebo-controlled, Latin American

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE